Royal Bank of Canada
IMVT icon

Royal Bank of Canada’s Immunovant IMVT Stock Holding History

Royal Bank of Canada’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
5,318
+2,917
+121% +$88.9K ﹤0.01% 4973
2026
Q1 		$60K Sell
2,401
-2,148
-47% -$55.6K ﹤0.01% 5395
2025
Q4 		$116K Buy
4,549
+780
+21% +$17.4K ﹤0.01% 5120
2025
Q3 		$61K Buy
3,769
+206
+6% +$3.33K ﹤0.01% 5737
2025
Q2 		$57K Sell
3,563
-18
-0.5% -$272 ﹤0.01% 5867
2025
Q1 		$61K Sell
3,581
-1,038
-22% -$21.7K ﹤0.01% 5491
2024
Q4 		$114K Sell
4,619
-5,064
-52% -$144K ﹤0.01% 5256
2024
Q3 		$276K Sell
9,683
-10,659
-52% -$314K ﹤0.01% 4567
2024
Q2 		$537K Buy
20,342
+1,845
+10% +$52.5K ﹤0.01% 3957
2024
Q1 		$597K Sell
18,497
-21,239
-53% -$775K ﹤0.01% 3842
2023
Q4 		$1.67M Sell
39,736
-305
-0.8% -$11.2K ﹤0.01% 3218
2023
Q3 		$1.54M Buy
40,041
+35,692
+821% +$807K ﹤0.01% 3085
2023
Q2 		$83K Buy
4,349
+470
+12% +$8.77K ﹤0.01% 5468
2023
Q1 		$60K Sell
3,879
-2,297
-37% -$39.9K ﹤0.01% 5525
2022
Q4 		$109K Buy
6,176
+4,635
+301% +$58.4K ﹤0.01% 5385
2022
Q3 		$9K Buy
1,541
+275
+22% +$1.34K ﹤0.01% 6476
2022
Q2 		$5K Sell
1,266
-2,267
-64% -$9.79K ﹤0.01% 6646
2022
Q1 		$20K Sell
3,533
-5,093
-59% -$31.7K ﹤0.01% 6604
2021
Q4 		$74K Buy
8,626
+4,228
+96% +$34.9K ﹤0.01% 6140
2021
Q3 		$38K Buy
4,398
+1,289
+41% +$11.6K ﹤0.01% 6322
2021
Q2 		$33K Buy
3,109
+758
+32% +$10.6K ﹤0.01% 6292
2021
Q1 		$38K Buy
2,351
+316
+16% +$8.33K ﹤0.01% 6058
2020
Q4 		$94K Buy
2,035
+344
+20% +$15.9K ﹤0.01% 5374
2020
Q3 		$60K Buy
1,691
+1,649
+3,926% +$49.6K ﹤0.01% 5266
2020
Q2 		$1K Buy
+42
New +$900 ﹤0.01% 6432

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Royal Bank of Canada's IMVT Position: Q2 2026 in Review

Royal Bank of Canada increased its Immunovant (IMVT) stake by 121% in Q2 2026, buying an estimated $88.9K and bringing the position to 5,318 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #4973.

Royal Bank of Canada first reported a position in IMVT in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.67M in Q4 2023. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Royal Bank of Canada held 5,318 shares of Immunovant worth $205K as of Q2 2026.
  • Royal Bank of Canada bought 2,917 Immunovant shares in Q2 2026, an estimated $88.9K.
  • Immunovant made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4973 holding.
  • Royal Bank of Canada first reported a position in Immunovant in Q2 2020 and has held it in 25 quarters since.
  • Royal Bank of Canada's Immunovant position peaked at $1.67M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.